68Ga-DOTATATE PET studies were mostly utilized for assessing SSTR2 expression and eligibility for [177Lu]Lu-DOTATATE therapy in both recurrent meningiomas [21] and pituitary carcinomas [41,68]. The gene discussed is SSTR2; the disease is pituitary adenocarcinoma.